Newport Beach’s IACTA Pharmaceuticals Inc. is one of four early-stage ophthalmology companies presenting at OCTANe’s Ophthalmology Technology Summit at Fashion Island Hotel on June 28.
The LaunchPad event is judged by an assortment of eyecare executives and venture capitalists.
IACTA is the only company of the four presenters that’s locally based.
Chief Executive Damon Burrows previously worked for Allergan when it was based in Irvine.
In 2017, it acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye.
